The effectiveness of switching from an originator biological agent to its biosimilar, or vice versa, for ankylosing spondylitis in real clinical practice
https://doi.org/10.14412/1996-7012-2020-4-157-160
Abstract
If standard therapy with nonsteroidal anti-inflammatory drugs is ineffective, biological drugs are usually prescribed for patients with active ankylosing spondylitis. These medicines are purchased in Russia not under their trade names, but under their international non-proprietary ones. This leads to the fact that either originator drugs or their biosimilars are purchased from time to time. For this reason, without a patient' and his/her attending physician's knowledge, the originator drug is switched to its biosimilar, or vice versa.
The paper describes two cases of multiple switches from an originator drug to its biosimilars, or vice versa, which are not clinically indicated. The results of analyzing these cases confirm the opinion that biosimilars may have a significantly different clinical efficacy from their originator drugs.
The paper describes two cases of multiple switches from an originator drug to its biosimilars, or vice versa, which are not clinically indicated. The results of analyzing these cases confirm the opinion that biosimilars may have a significantly different clinical efficacy from their originator drugs.
About the Authors
K. V. Sakharova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522, Russia
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522, Russia
M. V. Podryadnova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522, Russia
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522, Russia
Sh. F. Erdes
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522, Russia
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522, Russia
References
1. Erdes ShF, Badokin VV, Bochkova AG, et al. About the terminology of spondyloarthritis. Nauchno-prakticheskaya revmatologiya. 2015; 53(6):657-60. (In Russ.).
2. Erdes ShF, Dubinina TV, Abdulganieva DE, et al. Clinical characteristics of ankylosing spondylitis in real practice in Russia: results of a single-stage multicenter non-interventional EPICA2 study. Nauchno-prakticheskaya revmatologiya. 2016;54(S1): 10-4. (In Russ.).
3. Gaidukova IZ, Rebrov AP, Lapshina SA, et al. The use of non-steroidal anti-inflammatory drugs and genetically engineered biological drugs for the treatment of axial spondyloarthritis. Recommendations of the expert group on the study of spondyloarthritis at the all-Russian public organization «Association of rheumatologists of Russia». Nauchno-prakticheskaya revmatologiya. 2017;55(5):474-84. (In Russ.)
4. http://www.kremlin.ru/acts/bank/39223
5. https://www.fda.gov/media/108621/ download.
6. Nasonov EL. Biosimilars in rheumatology. Nauchno-prakticheskaya revmatologiya. 2016;54(6):628-40. (In Russ.).
7. Minutes of the meeting of the profile Commission of The expert Council of the Ministry of health of the Russian Federation on the specialty «Rheumatology» №17 dated October 22, 2016. Nauchno-prakticheskaya revmatologiya. 2016;54(6):715-17. (In Russ.).
Review
For citations:
Sakharova KV, Podryadnova MV, Erdes SF. The effectiveness of switching from an originator biological agent to its biosimilar, or vice versa, for ankylosing spondylitis in real clinical practice. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2020;14(4):157-160. (In Russ.) https://doi.org/10.14412/1996-7012-2020-4-157-160
Views:
657
Email this article 